Takeda, Bausch Health & more: 3 GI company key notes

Written by Rachel Popa | December 12, 2018 | Print  |

Here are three updates on GI companies from the past week:

Despite a small, vocal group of shareholders opposing Takeda's now $58 billion Shire takeover, 88 percent of the company's shareholders voted to approve the transaction.

Bausch Health plans to boost its gastroenterology arm by acquiring select assets of Synergy Pharmaceuticals

Olympus Medical Systems Co. and former Olympus executive Hisao Yabe both pled guilty to failing to report adverse events related to Olympus' duodenoscopes.

More articles on gastroenterology:
FDA finds higher than expected contamination rates after duodenoscope reprocessing: Best practices for avoiding fines
'Thinking outside the box' — 3 GI leaders on how their Sherman Prizes will advance Crohn's, IBD research
Internists file antitrust suit against American Board of Internal Medicine's maintenance of certification program — 6 insights

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.